|
Wed, 07/28/2021 - 04:53 |
Hepatitis cant wait - WHO commemorates World Hepatitis Day 2021 |
WHO |
|
Wed, 05/19/2021 - 08:52 |
Gov. Cooper, NCDHHS Encourages Screening, Testing and Vaccination During Hepatitis Awareness Month |
NC DHHS |
|
Thu, 07/25/2019 - 19:25 |
WHO urges countries to invest in eliminating hepatitis |
WHO |
|
Thu, 05/23/2019 - 09:21 |
VA now transplanting kidneys that are positive for hepatitis C |
US Veterans Affairs |
|
Mon, 05/06/2019 - 07:46 |
Maine CDC Recognizes May as National Hepatitis Awareness Month |
Maine State Gov... |
|
Fri, 05/03/2019 - 10:37 |
Governor Cooper, NCDHHS Promote Hepatitis Awareness, Encourage Vaccination, Testing |
NC DHHS |
|
Tue, 02/12/2019 - 03:47 |
Engineered immune cells produce antibodies to fight HIV |
Scripps Research |
|
Wed, 12/19/2018 - 03:02 |
Liver failure caused by attack on blood vessel cells |
Technical Unive... |
|
Wed, 12/05/2018 - 21:55 |
FDA Approves Genentechs Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer |
Genentech |
|
Mon, 12/03/2018 - 20:55 |
FDA Grants Priority Review to Genentechs Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer |
Genentech |
|
Sun, 12/02/2018 - 10:54 |
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID In Combination with Rituximab (R) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018 |
BMS |
|
Sat, 12/01/2018 - 05:02 |
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
Regeneron |
|
Wed, 11/28/2018 - 16:32 |
Fatty Liver Disease and the Link to Liver Cancer |
Roswell Park Ca... |
|
Wed, 11/28/2018 - 06:49 |
Celltrion and Teva Announce FDA Approval of TRUXIMA (rituximab-abbs), a Biosimilar to RITUXAN, for Three Non-Hodgkins Lymphoma Indications |
Teva Pharmaceutical |
|
Thu, 11/15/2018 - 20:29 |
ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine |
GlaxoSmithKline |
|
Mon, 11/12/2018 - 10:37 |
FDA Grants Priority Review to Genentechs Tecentriq in Combination With Abraxane for the Initial Treatment of People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer |
Genentech |
|
Tue, 11/06/2018 - 10:21 |
DHHS Confirms Death Related to Hepatitis A Outbreak |
NC DHHS |
|
Wed, 10/31/2018 - 15:26 |
Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities |
Genentech |
|
Tue, 10/30/2018 - 14:46 |
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen |
GlaxoSmithKline |
|
Mon, 10/29/2018 - 11:59 |
ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen |
GlaxoSmithKline |
|
Tue, 10/23/2018 - 11:09 |
REVLIMID (lenalidomide) Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma |
BMS |
|
Tue, 10/23/2018 - 00:36 |
Webinar: Hepatitis Prevention, Testing, and Treatment as Liver Cancer Prevention October 22, 2018 |
Prevent Cancer ... |
|
Tue, 10/23/2018 - 00:29 |
Webinar: Hepatitis Prevention, Testing, and Treatment as Liver Cancer Prevention |
Prevent Cancer ... |
|
Mon, 10/22/2018 - 09:34 |
Genentechs Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone |
Genentech |
|
Fri, 10/19/2018 - 21:22 |
Genentechs Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer |
Genentech |
